The DOI matches its Crossref record.
Randomized Comparison of Combination Chemotherapy With Etoposide, Bleomycin, and Either High-Dose or Standard-Dose Cisplatin in Children and Adolescents With High-Risk Malignant Germ Cell Tumors: A Pediatric Intergroup Study—Pediatric Oncology Group 9049 and Children's Cancer Group 8882
Open accessAbstract
Purpose: To determine in a randomized comparison whether combination chemotherapy with high-dose cisplatin (HDPEB) improves the event-free (EFS) and overall (OS) survival of children and adolescents with high-risk malignant germ cell tumors (MGCT) as compared with standard-dose cisplatin (PEB) and to compare the regimens' toxicity. Patients and Methods: Between March 1990 and February 1996, 299 eligible patients with stage III and IV gonadal and extragonadal (all stages) MGCT were enrolled onto this Pediatric Oncology Group and Children's Cancer Group study. Chemotherapy included bleomycin 15 units/m 2 on day 1, etoposide 100 mg/m 2 on days 1 through 5, and either high-dose cisplatin 40 mg/m 2 on days 1 through 5 (HDPEB; n = 149) or standard-dose cisplatin 20 mg/m 2 on days 1 through 5 (PEB; n = 150). Patients were evaluated after four cycles of therapy, and those with residual disease underwent surgery. Those with malignant disease in resected specimen received two additional cycles of their assigned regimen. Results: One hundred thirty-four eligible patients with advanced testicular (n = 60) or ovarian (n = 74) tumors and 165 with stage I to IV extragonadal tumors were enrolled. HDPEB treatment resulted in significantly improved 6-year EFS rate ± SE (89.6% ± 3.6% v 80.5% ± 4.8% for PEB; P = .0284). There was no significant difference in OS (HDPEB 91.7% ± 3.3% v PEB 86.0% ± 4.1%). Tumor-related deaths were more common after PEB (14 deaths v two deaths). Toxic deaths were more common with HDPEB (six deaths v one death). Other treatment-related toxicities were more common with HDPEB. Conclusion: Combination chemotherapy with HDPEB significantly improves EFS for children with high-risk MGCT. The OS is similar in both regimens, and the significant toxicity associated with HDPEB limits its use.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
McKenney, J. K., Heerema-McKenney, A., & Rouse, R. V. (2007) · Advances in Anatomic Pathology · doi:10.1097/pap.0b013e31803240e6 · Cited by 262
Challenges in the recruitment of adolescents and young adults to cancer clinical trials
Burke, M. E., Albritton, K., & Marina, N. (2007) · Cancer · doi:10.1002/cncr.23060 · Cited by 181
Self-citationSalvage high-dose chemotherapy for children with extragonadal germ-cell tumours
on behalf of the European Group for Blood and Marrow Transplantation Solid Tumours and Paediatric Disease Working Parties, De Giorgi, U., Rosti, G., Slavin, S., Yaniv, I., Harousseau, J. L., Ladenstein, R., Demirer, T., & Dini, G. (2005) · British Journal of Cancer · doi:10.1038/sj.bjc.6602724 · Cited by 85
Metadata
- Authors
- Cushing, B., Giller, R., Cullen, J. W., Marina, N. M., Lauer, S. J., Olson, T. A., Rogers, P. C., Colombani, P., Rescorla, F., Billmire, D. F., Vinocur, C. D., Hawkins, E. P., Davis, M. M., Perlman, E. J., London, W. B., & Castleberry, R. P.
- Venue
- Journal of Clinical Oncology
- Published
- 2004-07-01
- Volume
- 22
- Issue
- 13
- Pages
- 2691-2700
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2145672767
- Cited by
- 250
- References
- 0
- FWCI
- 10.30
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Randomized Comparison of Combination Chemotherapy With Etoposide, Bleomycin, and Either High-Dose or Standard-Dose Cisplatin in Children and Adolescents With High-Risk Malignant Germ Cell Tumors: A Pediatric Intergroup Study—Pediatric Oncology Group 9049 and Children's Cancer Group 8882. https://app.cochat.ai/papers/10.1200/jco.2004.08.015
- The paper
- Cushing, B., Giller, R., Cullen, J. W., Marina, N. M., Lauer, S. J., Olson, T. A., Rogers, P. C., Colombani, P., Rescorla, F., Billmire, D. F., Vinocur, C. D., Hawkins, E. P., Davis, M. M., Perlman, E. J., London, W. B., & Castleberry, R. P. (2004). Randomized Comparison of Combination Chemotherapy With Etoposide, Bleomycin, and Either High-Dose or Standard-Dose Cisplatin in Children and Adolescents With High-Risk Malignant Germ Cell Tumors: A Pediatric Intergroup Study—Pediatric Oncology Group 9049 and Children's Cancer Group 8882. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2004.08.015
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.